CLDN18 and familial pancreatic carcinoma: Our fındings offer preclinical proof-of-concept that the anti-CLDN18.2 ADC and anti-CLDN18.2-CD3 bispecific could be highly specific and potent against in vivo and in vitro models of gastric and pancreatic cancers.